Pfizer Inc
Close on Oct 30, 2026Market cap $173.95BP/E 40.2Yield 5.64%
Pfizer Deferred Revenue / Contract Liabilities by Quarter
Deferred Revenue / Contract Liabilities — Government COVID-19 supply agreements ($M) ($M)
Pfizer Deferred Revenue / Contract Liabilities: $1,400M in Q2 2026, down 26.3% from a year earlier. That is the lowest of the 14 quarters on record here.
Where the Q2 2026 figure comes from
Source: Form 10-Q (filed 2026-08-04) ↗
Advance customer/government payments and contracted multi-year delivery obligations under ASC 606.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Deferred Revenue / Contract Liabilities — Government COVID-19 supply agreements ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 28, 2026 | 1,400 | -26.3% | Form 10-Q (filed 2026-08-04) ↗ |
| Q1 2026 | Mar 29, 2026 | 1,500 | -21.1% | Form 10-Q (filed 2026-05-05) ↗ |
| Q4 2025 | Dec 31, 2025 | 1,500 | -31.8% | Form 10-Q (filed 2026-08-04) ↗ |
| Q3 2025 | Sep 28, 2025 | 1,800 | -48.6% | Form 10-Q (filed 2025-11-04) ↗ |
| Q2 2025 | Jun 29, 2025 | 1,900 | -55.8% | Form 10-Q (filed 2025-08-05) ↗ |
| Q1 2025 | Mar 30, 2025 | 1,900 | -53.7% | Form 10-Q (filed 2025-05-05) ↗ |
| Q4 2024 | Dec 31, 2024 | 2,200 | -56.9% | Form 10-K (filed 2026-02-26) ↗ |
| Q3 2024 | Sep 29, 2024 | 3,500 | – | Form 10-Q (filed 2024-11-04) ↗ |
| Q2 2024 | Jun 30, 2024 | 4,300 | – | Form 10-Q (filed 2024-08-05) ↗ |
| Q1 2024 | Mar 31, 2024 | 4,100 | – | Form 10-Q (filed 2024-05-08) ↗ |
| Q4 2023 | Dec 31, 2023 | 5,100 | – | Form 10-K (filed 2025-02-27) ↗ |
| Q3 2022 | Oct 2, 2022 | 6,200 | – | Form 10-Q (filed 2022-11-09) ↗ |
| Q2 2022 | Jul 3, 2022 | 3,900 | – | Form 10-Q (filed 2022-08-10) ↗ |
| Q1 2022 | Apr 3, 2022 | 3,300 | – | Form 10-Q (filed 2022-05-11) ↗ |
Breakdown
What makes up deferred Revenue / Contract Liabilities
- Government COVID-19 contract liabilities — Current ($M)521 · Q2 2026
- Government COVID-19 contract liabilities — Noncurrent ($M)855 · Q2 2026
- Remaining Performance Obligations (RPO) — Comirnaty multi-year contracts ($M)2,000 · Q2 2026
- Remaining Performance Obligations (RPO) — Paxlovid multi-year contracts ($M)965 · Q2 2026
- Remaining Performance Obligations (RPO) — Total [legacy through Q3 2023] ($M)9,000 · Q3 2023
- Unconditional Long-Term Purchase Obligations — Manufacturing, API & R&D ($M)–
Cite this data
StockData. (2026). Pfizer Deferred Revenue / Contract Liabilities ($M), quarterly Q1 2022–Q2 2026 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/def-rev-gov-covid-tot
See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.